Developing a Vaccine for Ebola

The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel prime-boost preventive vaccine regimen against Ebola Virus Disease (EVD). In a prime-boost vaccine regimen, individuals are first given a dose to prime the immune system, and then a boost dose which is intended to enhance the immune response and increase the duration of the response.

Between them the EBOVAC1 and EBOVAC2 projects are assessing – through several clinical trials conducted in phases in Europe and Africa – the safety, tolerability and immunogenicity of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

To expedite the development of the vaccine regimen, some stages of the trials are being carried out in parallel and are therefore being coordinated by two separate teams within the EBOVAC1 and EBOVAC2 projects.

Find out more about the EBOVAC trials:

Phase 1

Phase 2 

EBOVAC-Salone 

Ebola signs in Freetown, Sierra Leone (Dr D Watson-Jones)

Ebola signs in Freetown, Sierra Leone (Credit: Dr D Watson-Jones)

EBOVAC1 and EBOVAC2 are working closely with the EBODAC vaccine deployment and compliance project, and the EBOMAN vaccine manufacture capability project.

Find out more about these projects:

EBODAC – Vaccine deployment and compliance

EBOMAN – Vaccine manufacture capability

 

The Ebola vaccine projects are part of the Innovative Medicines Initiative Ebola+ programme

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2017 Ebovac | Terms and Conditions | WordPress development by Toast.